IDH1 and glioblastoma: Median overall survival (OS) of all glioblastoma patients in this study cohort was 11.6 months (95% CI 10.7–12.3), and 10.9 months (95% CI 10.3–11.8) in the cohort with proven IDH-wildtype (1,115/1,420).